Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
|Articles|June 29, 2013
Supplements and Featured Publications
- Hereditary Angioedema: Facilitating Diagnosis and Optimizing Clinical and Economic Outcomes [CPE/CME
- Volume 19
- Issue 7 Suppl
Hereditary Angioedema: Facilitating Diagnosis and Optimizing Clinical and Economic Outcomes
Advertisement
Instructions
After reading “Hereditary Angioedema: Facilitating Diagnosis and Optimizing Clinical and Economic Outcomes,” complete the program evaluation and select the single best answer to each of the posttest questions.
A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.
Articles in this issue
about 13 years ago
Management and Prevention of Hereditary Angioedema Attacksover 13 years ago
Managed Care Implications of Hereditary AngioedemaAdvertisement
Related to this article
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Tavapadon for Parkinson Disease Approved by FDA
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5